Prasad G. Iyer, M.D., M.S.

The purpose of this study is to measure DNA yield from esophageal cytology samples collected with the Cytosponge device in comparison to historical ranges observed from esophageal cytology samples collected with the EsophaCap (from IRB 15-004540).

Also, to evaluate MDM levels and accuracy of the Oncoguard® Esophagus test (OGE test) for the detection of methylated DNA markers in Cytosponge-collected esophageal cytology samples in comparison to historical ranges of MDMs and accuracy observed from esophageal cytology samples collected with the EsophaCap (from IRB 15-004540).

Inclusion Criteria:

• Patients with Barrett’s Esophagus (BE) or Esophageal Adenocarcinoma (EAC) that are planned for Endoscopic Submucosal Dissection (ESD) treatment.

Exclusion Criteria: 

• Patients without BE or EAC or that are not planned for ESD treatment.

The purpose of this multicenter, prospective, single arm, non-randomized clinical trial to evaluate the safety and efficacy of the C2 CryoBalloon Focal Ablation System (CbFAS) for the treatment of persistent dysplasia or intestinal metaplasia (IM) in the tubular esophagus after 3 or more radiofrequency ablations (RFA) for dysplastic BE, or <50% eradication of Barrett's Esophagus (BE) after 2 RFA treatments.

The purpose of this study is to compare the effectiveness of two approaches for the management of Barrett's Esophagus (BE) and Low-grade Dysplasia (LGD), endoscopic surveillance and endoscopic eradication therapy (EET), using accepted clinical endpoints of neoplastic progression [high-grade dysplasia (HGD)/mucosal esophageal adenocarcinoma (EAC)/invasive EAC] as determined by a blinded central committee.

The purpose of this study is to see if different depths of submucosal tumor invasion in esophageal cancer can predict lymph node involvement and survival.

The investigators hypothesize that intensive acid suppression with a long acting high potency proton pump inhibitor (dexlansoprazole) will lead to a greater decrease in levels of inflammatory mediators (compared to conventional PPIs) in the esophagus, which could potentially lead to decreased recurrence of intestinal metaplasia following endoscopic ablation.

To assess attitudes toward screening for esophageal adenocarcinoma (EAC) and Barrett's esophagus (BE) in the community.

To develop a population based clinical risk factor prediction model for the diagnosis of BE and identify novel risk factors for BE which would make population based screening more efficient. This will be an important first step in identifying the target population for BE screening, another crucial component of making screening feasible and efficient.

This study is being done to help understand why some people with an increased amount of central obesity, without gastroesophageal reflux, develop changes to the lining of their esophagus that can potentially lead to esophageal adenocarcinoma (cancer).

The purpose of this study is to evaluate if the capsule sponge device can detect the presence of Barrett's Esophagus.

Will oral supplementation with Omega 3 free fatty acids in obese Barrett's esophagus subjects downregulate pro-neoplastic and pro-inflammatory pathways in the esophagus to anti-inflammatory pathway?

To evaluate the efficacy and safety of the CryoBalloon Focal Ablation System for the treatment of previously-untreated ("treatment naïve") Barrett's Esophagus (BE)

To prospectively assess the functional aspects of the the esophageal squamous epithelial barrier and correlate this with tissue inflammation and intercellular space dilation in patients who have successfully completed endoscopic therapy for Barrett's Esophagus related metaplasia.

Will EG Scan (transnasal endoscopy) determine presence of Barrett's Esophagus, esophagitis and hiatal hernia as well as standard sedated endoscopy.

The purpose of this study is to develop an evidence-based management decision aid for patients who have Barrett's Esophagus with low grade dysplasia, called BE Choice. To evaluate the impact of the developed decision aid (BE Choice) on patient-centered outcomes, assessments will be made of patient knowledge, decision conflict, patient involvement in decision-making, treatment choice, and outcomes when compared to ‘usual specialist care’.

Is waist to hip ratio (WHR), waist circumference (WC), (as markers of visceral adiposity) associated with an increase in acidic and non acidic reflux as well as systemic inflammation involving esophageal mucosa, thereby increasing esophageal injury and predisposing to subsequent development of Barrett's esophagus (BE)?

This study is to identify potential markers from esophageal biopsies and brush cytology for feasibility of use in stool specimens for detection of Barretts Esophagus.